



Celsion Corporation Announces Time of Oral Presentation at International Vaccines Congress

October 16, 2021

Chief Science Officer Dr. Richard Assari to Deliver Virtual Presentation Monday, October 18th 7:30 a.m. Boston, Time

LYNNHAVEN, N.J., Oct. 16, 2021 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-mediated immunology and next-generation vaccine solutions, announced that it will be presenting at the International Vaccines Congress, a key in-person event, on Monday, October 18, 2021 at 7:30 a.m. Eastern time (see link for Eventbrite event). Dr. Richard Assari, Chief Science Officer, will deliver his presentation at the International Vaccines Congress. A key in-person event, the "Technology of DNA Vaccines Based on Multivalent, Vector and Synthetic DNA Delivery Systems," will be available on Celsion's website at that time and can be viewed [here](#).

About the FLACCORD Platform

FLACCORD (Clinical Vaccine Adjuvant) platform technology will be critical to commercializing products that address a broad range of next-generation DNA vaccines. An extension of Celsion's ProDNA technology, FLACCORD is a DNA vaccine adjuvant platform technology designed to improve DNA vaccine immunogenicity. The platform is designed to improve multiple antigen delivery and presentation methods. It is delivered as a synthetic delivery system and has the potential to be easily modified to create vaccine adjuvants for a wide range of infectious disease, including:

- **Viral Vaccines:** FLACCORD may offer broad spectrum and mucosal response (enhanced by targeting multiple antigens in a single plasmid vector).
- **Antitumor Therapy:** FLACCORD vaccine is a DNA plasmid-based antigen that can result in durable antigen exposure and a robust immune response to viral antigens.
- **Therapeutic Vaccination:** FLACCORD allows for easy grafts to compatible with immunogenic vaccine therapy and distribution.

• **Dosage & Administration:** FLACCORD is a synthetic delivery system that should require a simple injection or special equipment to deliver its payload.

About Celsion Corporation

Celsion is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies, RNA-based therapies and antibody therapeutics through clinical trials and commercial commercialization. The company's pipeline portfolio includes 5B11, a DNA-based immunotherapy for the localized treatment of prostate cancer. Celsion also has two heavily stage pipeline technologies for the development of novel nucleic acid-based immunotherapies and other vaccines (DNA or RNA therapies). Both use novel systems, not viral vectors, with demonstrated capability to localize and cellular localization. For more information on Celsion, visit [www.celsion.com](#).

Forward Looking Statements

Investing involves risks. There are risks inherent in investing in our common stock. Investors should carefully consider the risks and uncertainties described in this press release and the company's annual report on Form 10-K for the year ended December 31, 2020, and its quarterly reports on Form 10-Q for the quarters ended March 31, 2021 and June 30, 2021, and possible future issuances of 5B11 CAPIF or other common stock. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability of the Company's platform to provide broad commercial success (COVID-19 and possible future issuances of 5B11 CAPIF or other common stock) or other common stock. The success of a platform or technology platform for creating or producing vaccines with the 5B11 CAPIF platform depends on COVID-19, unforeseen changes in the course of research and development of vaccine technologies, access to resources, possible delays in regulatory approvals, regulatory changes, and other risks detailed from time to time in the Company's periodic filings with the Securities and Exchange Commission. Other factors that might affect the company's financial performance include the success of our research and development efforts, the availability of financing.

CONTACT:

Celsion Corporation
Richard Assari, Chief Science Officer
assari@celsion.com
781.434.1000

USX Science Relations
USX Science Relations
USX Science Relations



Source: Celsion CORP